Inka Wahl, Andreas Feige, Bernd Löwe, Christina Weiler‐Normann, Matthias Rose, Ansgar W. Lohse, Christoph Schramm – 13 June 2014

Supelana Christina, Rachel A. Annunziato, Thomas D. Schiano, Ravinder Anand, Swapna Vaidya, Kelley Chuang, Yelena Zack, Sander Florman, Benjamin L. Shneider, Eyal Shemesh – 13 June 2014 – Nonadherence to immunosuppressants may play a role in late rejection in liver transplant recipients. In children, emerging data suggest that adherence can be measured through the computation of the standard deviation (SD) of consecutive blood levels of tacrolimus, which results in a number that reflects the degree of variability between individual measures: the medication level variability index (MLVI).

Nimzing G. Ladep, Anthony C. Dona, Matthew R. Lewis, Mary M.E. Crossey, Maud Lemoine, Edith Okeke, Yusuke Shimakawa, Mary Duguru, Harr F. Njai, Haddy K.S. Fye, Makie Taal, John Chetwood, Ben Kasstan, Shahid A. Khan, Deborah A. Garside, Anisha Wijeyesekera, Andrew V. Thillainayagam, Edmund Banwat, Mark R. Thursz, Jeremy K. Nicholson, Ramou Njie, Elaine Holmes, Simon D. Taylor‐Robinson – 13 June 2014 – There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha‐fetoprotein (AFP) is too low for this purpose.

Nimzing G. Ladep, Anthony C. Dona, Matthew R. Lewis, Mary M.E. Crossey, Maud Lemoine, Edith Okeke, Yusuke Shimakawa, Mary Duguru, Harr F. Njai, Haddy K.S. Fye, Makie Taal, John Chetwood, Ben Kasstan, Shahid A. Khan, Deborah A. Garside, Anisha Wijeyesekera, Andrew V. Thillainayagam, Edmund Banwat, Mark R. Thursz, Jeremy K. Nicholson, Ramou Njie, Elaine Holmes, Simon D. Taylor‐Robinson – 13 June 2014 – There is no clinically applicable biomarker for surveillance of hepatocellular carcinoma (HCC), because the sensitivity of serum alpha‐fetoprotein (AFP) is too low for this purpose.

Yi‐Wen Huang, Sien‐Sing Yang, Szu‐Chieh Fu, Ting‐Chuan Wang, Cheng‐Kai Hsu, Ding‐Shinn Chen, Jui‐Ting Hu, Jia‐Horng Kao – 11 June 2014 – The effect of diabetes on cirrhosis, its decompensation, and their time relationship in chronic hepatitis C (CHC) patients remains unclear. We conducted a nation‐wide cohort study by using the Taiwanese National Health Insurance Research Database, which is comprised of data from >99% of the entire population. Among having randomly sampled 1 million enrollees, 6,251 adult CHC patients were identified from 1997 to 2009.

Kangsheng Tu, Jiachu Li, Vikas K. Verma, Chunsheng Liu, Daniel D. Billadeau, Georg Lamprecht, Xiaoyu Xiang, Luyang Guo, Renumathy Dhanasekaran, Lewis R. Roberts, Vijay H. Shah, Ningling Kang – 10 June 2014 – Liver microenvironment is a critical determinant for development and progression of liver metastasis. Under transforming growth factor beta (TGF‐β) stimulation, hepatic stellate cells (HSCs), which are liver‐specific pericytes, transdifferentiate into tumor‐associated myofibroblasts that promote tumor implantation (TI) and growth in the liver.

Edoardo G. Giannini, Alessandro Cucchetti, Alessandro Vitale – 10 June 2014

Joel Wedd, Kiran M. Bambha, Matt Stotts, Heather Laskey, Jordi Colmenero, Jane Gralla, Scott W. Biggins – 10 June 2014 – The Model for End‐Stage Liver Disease (MELD) score has reduced predictive ability in patients with cirrhosis and MELD scores ≤ 20. We aimed to assess whether a 5‐stage clinical model could identify liver transplantation (LT) candidates with low MELD scores who are at increased risk for death. We conducted a case‐control study of subjects with cirrhosis and MELD scores ≤ 20 who were awaiting LT at a single academic medical center between February 2002 and May 2011.

Georg Auzinger, Christopher Willars, Robert Loveridge, Thomas Best, Andre Vercueil, Andreas Prachalias, Michael A. Heneghan, Julia Wendon – 10 June 2014

Jacinta A. Holmes, Gail V. Matthews, Alexander J. Thompson, on behalf of the CHARIOT Study Group – 10 June 2014